Welcome to our dedicated page for Alaunos Therapeutics SEC filings (Ticker: TCRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alaunos Therapeutics, Inc. (TCRT) SEC filings page on Stock Titan provides direct access to the companys regulatory disclosures, including current reports, registration statements and financing-related documents. These filings show how Alaunos describes its business as combining T-cell receptor (TCR) cell therapy for solid tumors with a preclinical-stage obesity and metabolic health drug development program centered on a small molecule candidate.
Through its Forms 8-K, Alaunos reports material events such as strategic reprioritization steps, capital raises, changes in executive leadership, governance matters and listing status. Recent 8-Ks detail a registered direct offering of common stock and pre-funded warrants under a shelf registration statement on Form S-3, a private offering of Series A-2 Convertible Preferred Stock with dividend, voting and conversion terms, and a settlement and release agreement with The University of Texas M.D. Anderson Cancer Center regarding unpaid invoices under a research and development agreement. Other 8-Ks describe Nasdaq notices of non-compliance and subsequent confirmation that the company regained compliance, as well as stockholder approvals of amendments to increase authorized common stock and adjust capital structure.
Alaunos Form S-1 registration statement outlines its identity as a preclinical-stage obesity and metabolic health drug development company, while also summarizing its history as a clinical-stage oncology-focused cell therapy company and the August 2023 decision to wind down its TCR-T Library Phase 1/2 trial. The S-1 also explains an equity purchase agreement and related warrant that allow the company, at its discretion, to sell common stock to an institutional investor up to a specified aggregate amount.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, such as financing structures, conversion prices, dividend rights, share authorization changes and listing compliance updates. Users can quickly scan material agreements, capital markets transactions and corporate actions, and then open the full EDGAR documents for detailed review. This page is a central resource for understanding how Alaunos presents its strategy, risks, and capital structure in official SEC documents.
Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics director Jaime Vieser reported an equity award. Vieser received a grant of 6,515 shares of Alaunos Therapeutics common stock at a price of $2.59 per share, increasing his directly held stake to 38,853 shares.
In addition to these direct holdings, the filing lists 13,503 shares held indirectly through Brushwood LLC, where Vieser is the manager, and 2,100 shares held indirectly for the benefit of his children.
Postma Robert W reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics director Robert W. Postma reported a stock-based compensation grant. On April 29, 2026, he received 6,274 shares of Alaunos Therapeutics common stock at $2.59 per share, issued in lieu of board fees. Following this grant, he directly holds 50,146 shares of common stock.
In addition to his direct holdings, Postma has indirect ownership interests, including 62,416 shares held by WaterMill Asset Management Corp., where he serves as principal, and 24 shares held in his spouse’s IRA. The filing does not show any open-market purchases or sales, only this compensation-related award and updated ownership positions.
Alaunos Therapeutics, Inc. director Michael Allen Jerman received a grant of 6,032 shares of common stock on April 29, 2026, as a stock award issued in lieu of board fees. Following this compensation-related acquisition, he directly holds a total of 15,621 shares of Alaunos common stock.
Alaunos Therapeutics, Inc. filed an amendment to its annual report to add Part III information that had been omitted from the original Form 10-K. The amendment details the company’s board and governance structure, executive and director compensation, and security ownership of key stockholders and management.
The filing confirms a four‑member board, led by CEO and chair Holger Weis, and describes committee membership and independence under Nasdaq rules. It also outlines employment and consulting agreements, equity incentive plans, ownership concentrations among major holders, and audit fees paid to Cherry Bekaert LLP, without changing previously reported financial statements.
Alaunos Therapeutics, Inc. reported that Nasdaq notified the company on April 9, 2026 that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity to remain listed on the Nasdaq Capital Market. The company’s Form 10-K for the year ended December 31, 2025 reported stockholders’ equity of $2,153,000.
The company also does not currently meet Nasdaq’s alternative continued listing standards of a $35 million market value of listed securities or $500,000 in net income from continuing operations in the required periods. Alaunos has 45 calendar days from the date of the notice, until May 26, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to evidence compliance if the plan is accepted.
The company intends to submit a compliance plan and is evaluating potential actions to regain compliance. If the plan is not accepted, or if compliance is not regained within any extension, Alaunos would have the right to request a hearing before an independent Nasdaq panel, which would temporarily stay any suspension or delisting. Trading in the company’s securities is expected to continue following this disclosure if made within the required timeframe.
Alaunos Therapeutics, Inc. reports a strategic pivot to an early-stage, oral small‑molecule obesity and metabolic disorders program while warning of severe financial strain. For 2025, the company recorded a net loss of $4.2 million and an accumulated deficit of $924.6 million as of December 31, 2025.
Cash and cash equivalents were about $1.4 million, which management expects will fund operations only into the second quarter of 2026, raising substantial doubt about continuing as a going concern. Stockholders’ equity was $2.2 million, below Nasdaq’s $2.5 million equity requirement, creating renewed delisting risk.
The lead obesity candidate, ALN1003, has shown dose-dependent weight loss and metabolic improvements in diet‑induced obesity mouse models but remains in preclinical, non‑GLP studies with significant scientific, regulatory, financing, and execution risks. The company now has only one full-time employee and relies heavily on consultants, has identified a material weakness in internal control due to limited personnel, and highlights the possibility that failure to fund or advance the program could lead the board to consider dissolution and liquidation.
Alaunos Therapeutics’ shareholders led by Adrian Price filed Amendment No. 4 to their Schedule 13D and proposed a major new financing and governance change. The group reports beneficial ownership of 189,061 shares of common stock, representing 8.6% of the company.
In a letter dated February 24, 2026, Price proposed that HexagonONE Ltd, Alimenta Holding Limited and Krakatau Holding Limited invest $7,000,000 in equity or equity-linked securities via a private placement, with pricing to be negotiated and closing after board approval, documentation and any required Nasdaq shareholder approval. The letter says this transaction, if completed, is expected to result in a change of control.
The shareholders asked the board to meet within five business days to negotiate terms, pressed for the appointment of Gerald Bruce as a director, and stated they may buy additional shares, pursue a tender offer or launch an investor relations campaign if the board does not engage. Amendment No. 4 also corrects and updates the list of reporting persons, their addresses and related powers of attorney.
Alaunos Therapeutics reported positive preclinical proof-of-concept data for ALN1003, its lead oral, non-hormonal small-molecule drug candidate for obesity and related metabolic disorders. In two diet-induced obesity mouse studies, ALN1003 produced dose-related body weight loss, favorable body composition changes, and reduced liver weight compared with untreated controls.
ALN1003-treated mice also showed lower liver injury enzymes (ALT, AST, ALP), improved metabolic biomarkers such as glucose and total cholesterol, and macroscopic signs of reduced liver and white fat accumulation. These non-GLP results will guide further preclinical, formulation, manufacturing, and IND-enabling work. Alaunos reported cash and cash equivalents of about $1.9 million as of September 30, 2025, with its cash runway extending into the second quarter of 2026 and plans to seek additional financing.
Alaunos Therapeutics shareholders led by Adrian Price filed an amended Schedule 13D reporting beneficial ownership of 189,061 common shares, or 8.6% of the company. The group sent a letter proposing a $7,000,000 private placement in equity or equity-linked securities by Hexagon ONE Inc, Alimenta Holding Inc and Krakatau Holding Inc, which is anticipated to result in a change of control if completed.
The investors asked the board to negotiate a term sheet within five business days and reiterated their nomination of Gerald Bruce to the board. They indicated they may buy additional shares in the market, launch a tender offer, or run an investor relations campaign if the board does not engage.
Alaunos Therapeutics, Inc. director Jerman Michael Allen reported receiving 5,406 shares of common stock on 01/12/2026 at $2.89 per share. According to the filing, these shares were issued in lieu of cash board fees, meaning the director took stock as compensation for board service. Following this transaction, he beneficially owns 9,589 shares of Alaunos common stock, held directly.